Many of the drugs used in treating acute lymphoblastic leukaemia (ALL) cause gastrointestinal symptoms, particularly nausea and vomiting. Methotrexate commonly causes mucositis and occasionally diarrhoea; it has been shown to alter jejunal morphology' and, more recently, has been implicated in causing impaired xylose absorption in children with leukaema.2 Sporadic reports have appeared implicating methotrexate in causing a clinical malabsorption syndrome. 3 Seven children with ALL exhibited clinical and biochemical criteria of malabsorption while on maintenance therapy, which included regular weekly methotrexate. Patients
In the 5 years to March 1981, 81 children were diagnosed as having ALL at this hospital. The mdajority of patients were treated according to Medical Research Council UK ALL trials. Fortyfive were treated with maintenance regimens using intermittent methotrexate, 6-mercaptopurine (6-MP) cytosine arabinoside, vincristine, and prednisolone. (UK ALL IV, UK ALL V 'intermittent', and UK ALL VI). Thirty-six were treated with regimens using weekly methotrexate, 6-MP, vincristine, and prednisolone (UK ALL V 'continuous', UK ALL V 'gaps', and UK ALL VIII) ( Table 1) .
During this time 7 of the patients on maintenance therapy, including weekly methotrexate, presented with gastrointestinal symptoms that suggested a severe enteropathy. Six of these patients were entered into UK ALI, trials. The first patient was initially entered into UK ALL IV but after 18 months was changed to UK ALL V (gaps) maintenance treatment. Two patients were entered into UK ALL V (1 continuous, 1 gaps) and 3 patients into UK ALL VIII. The other patient was too young at diagnosis for entry into the trials but followed the UK ALL V (gaps) schedule except that cranial irradiation was omitted and regular intrathecal methotrexate substituted. 
